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Multiple	myeloma	(MM)	is	a	terminally	differentia­
ted	clonal	B­cell	neoplasm	characterized	by	the	ac­
cumulation	of	malignant	plasma	cells	(PCs)	within	the	
bone	marrow	(BM).	 Its	prognosis	 is	highly	variable,	
with	survival	 ranging	 from	a	 few	days	 to	more	 than	
10	years	[1,	2].	A	median	survival	of	about	3	years	was	
obtained	with	conventional	chemotherapy.	Despite	
improvements	in	the	clinical	management	of	patients	
in	the	past	decade,	especially	with	the	use	of	high­dose	
therapy	followed	by	autologous	stem	cell	transplanta­
tion	[3]	and	with	the	use	of	new	drugs	such	as	thalido­
mide,	lenalidomide	and	proteasome	inhibitors	[4–6],	
MM	remains	incurable.	Therefore,	it	appears	essential,	
at	diagnosis,	to	recognize	clinical	or	biological	parame­
ters	predicting	the	outcome	and	identifying	patients	
for	whom	an	aggressive	therapy	would	be	indicated.	
Molecular	 cytogenetic	 studies	have	 revealed	 that,	
to	a	great	extent,	the	clinical	heterogeneity	of	MM	is	
dictated	by	the	cytogenetic	aberrations	present	in	the	
clonal	plasma	cells.	Karyotypic	deletion	of	chromo­
some	13,	hypodiploidy,	and	molecular	cytogenetics	are	
specific	independent	prognostic	factors	for	accurate	
risk	stratification	in	MM	[7].	
Although	there	are	many	reports	that	cytogenetic	
changes	are	associated	with	prognosis,	cytogenetic	
studies	in	MM	are	hampered	by	the	hypoproliferative	
nature	of	 clonal	PCs	 in	MM.	Abnormal	 karyotypes	
have	been	reported	only	in	30–45%	of	de novo	cases,	
and	35–60%	in	previously	treated	and	relapsing	pa­
tients	 [8].	Fluorescence	 in situ	 hybridization	 (FISH)	
overcomes	 the	 limitations	of	standard	cytogenetics	
and	allows	for	the	detection	of	numerical	and	struc­
tural	chromosomal	abnormalities	in	both	metaphase	
spreads	and	 interphase	nuclei.	Thus,	FISH	 is	an	at­
tractive	alternative	 for	 evaluation	of	 chromosomal	
aberrations	of	MM.	In	contrast	with	the	incidence	of	
abnormal	karyotypes	detected	 in	MM	with	conven­
tional	cytogenetics,	 studies	using	FISH	 techniques	
have	 identified	chromosome	changes	 in	BM	PCs	 in	
more	than	80%	of	the	patients	[9,	10].	Since	PCs	are	
low	in	BM	samples	of	patients	with	MM,	we	enriched	
CD138+	myeloma	cells	by	magnetic­activated	cell	sort­
ing	(MACS)	to	improve	the	sensitivity	of	the	interphase	
FISH	method.	
Here	we	 investigated	the	most	prevalent	genetic	
changes	 in	patients	with	MM.	We	performed	 inter­
phase	FISH	using	6	probes	that	have	been	reportedly	
related	to	MM	and	studied	BM	samples	from	48	newly	
diagnosed	patients.	We	suggested	that	the	detection	
of	at	least	these	three	genetic	changes,	13q14	dele­
tion,	illegitimate	IGH	rearrangements,	and	Amp1q12,	
would	be	helpful	for	patients	with	MM.
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Materials and Methods
Patients and BM samples. We	studied	48	newly	
diagnosed	and	untreated	MM	patients.	BM	samples	of	
patients	with	MM	were	obtained	at	diagnosis	and	under	
informed	consent,	and	enriched	for	mononuclear	cells	
using	the	Ficoll­gradient	centrifugation	method.	Myeloma	
cells	were	enriched	by	MACS	using	 the	CD138­spe­
cific	monoclonal	antibody	B­B4.	CD138+	cell	suspensions	
fixed	in	methanol/acetic	acid	(3	:	l)	and	stored	at	–20	°C.
interphase fluorescence in situ hybridization. 
Slides	were	treated	with	100	μg/ml	RNAse	for	30	min	
at	37	 ˚C	 followed	by	2	×	SSC	washing	 for	5	min	×	2	
and	 treated	with	0.005%	pepsin	 for	5	min	at	37	 ˚C,	
then	washed	 twice	 for	 5	min	 each	 in	 phosphate	
buffered	saline	 (PBS)	and	dehydrated	 in	 increasing	
concentrations	of	ethanol	(70,	85	and	100%)	at	room	
temperature	for	1	min	in	each	solution.	The	slides	were	
denatured	in	a	70%	formamide	solution	at	72	˚C	for	
2	min,	dehydrated	in	an	ethanol	series	and	air­dried.	
Probes	(3	μl)	were	mixed	well	with	hybridization	buffer	
(5	μl)	and	denatured	at	72	˚C	for	5	min.	Probes	were	
applied	immediately	to	slides	and	hybridized	at	37	˚C	
overnight.	After	hybridization,	 slides	were	washed	
at	72	 ˚C	 for	2	min	 in	0.4	×	SSC/0.3%	NP­40	and	 in	
2	×	SSC/0.	1%	NP­40	for	1	min	at	room	temperature.	
Slides	were	 then	air­dried	and	mounted	using	10	μl	
of	 4’,6’­diamidino­2­phenylindole	 (DAPI	 II)	 (Vysis,	
Downers	Grove,	USA)	counterstain	for	1	h.
To	detect	a	deletion	on	 the	 long	arm	of	chromo­
some	13,	we	used	D13S319	SpectrumGreen	probe.	To	
determine	the	translocations	involving	IGH,	we	used	the	
LSI	 IGH/IGHV	dual­color,	break­apart	rearrangement	
probe;	 the	LSI	 IGH/CCND1	dual­color,	dual­fusion	
translocation	probe;	 the	LSI	 IGH/FGFR3	dual­color,	
dual­fusion	translocation	probe;	the	LSI	IGH/MAF	dual­
color,	dual­fusion	translocation	probe.	To	detect	am­
plifications	of	1q,	we	used	the	CEP	1	SpectrumOrange	
Probe	at	1q12.	All	probes	purchased	from	Vysis,	USA.	
Fluorescent	images	were	captured	with	epifluores­
cence	microscope	(Leica	DRMA2,	Germany)	equipped	
with	CCD	camera	(AI	company,	UK),	and	using	appro­
priate	filters.	Five	hundred	nuclei	were	analyzed	for	each	
probe.	Chromosome	13	deletions	were	identified	with	
only	one	signal	in	interphase	cells	using	D13S319	probe.	
Rearrangements	of	the	14q32	region	were	determined	
by	means	of	a	dual­color	FISH	assay.	Our	strategy	was	
based	on	identifying	the	split	and	translocation	of	these	
sequences	on	 interphase	nuclei.	We	 first	 looked	 for	
illegitimate	IgH	rearrangements	with	separate	signals	
using	14q32	(IGHC/IGHV)	probe,	which	mapping	at	the	
centromeric	and	telomeric	borders	of	the	IgH	locus	were	
labeled	with	SpectrumGreen	and	SpectrumOrange,	re­
spectively.	Then	using	LSI	IGH/CCND1,	LSI	IGH/FGFR3	
and	LSI	IGH/MAF	probes,	we	detected	fused	signals	in	
patients	with	14q32	rearrangements.	Amplifications	of	
1q	were	identified	with	more	than	two	signals	in	inter­
phase	cells.	
BM	cells	samples	of	8	cytogenetically	normal	per­
sons	were	used	as	normal	controls.	The	cutoff	levels	
for	positive	values	for	each	probe	in	I­FISH,	which	were	
set	at	the	mean	of	normal	controls	plus	three	standard	
deviations,	were	as	 follows:	del(13q14),	 10%;	 IgH	
rearrangements	(IGHC/IGHV),	8.9%;	t(11;14),	9.1%;	
t(4;14),	5%;	t(14;16)	6.5%	and	Amp1q12,	5%.
statistical analysis. χ2	or	Fisher’s	exact	tests	were	
used	for	between­group	comparison	of	the	discrete	
variables.	
results
Characteristics of the patients. 48	newly	diagnosed	
and	untreated	MM	patients	were	studied.	There	were	
33	males	and	15	females	(the	male	to	female	ratio	was	
2.2	to	1),	with	a	median	age	of	65	(range	45~77)	years.	
Out	of	48	patients,	the	types	of	M­protein	were	IgGκ	in	21,	
IgGλ	in	11,	IgAκ	in	9,	IgAλ	in	5,	and	only	kappa	light	chain	
in	2	patients.	According	to	Durie	and	Salmon	staging	[11],	
9	were	stage	I,	16	were	stage	II,	and	23	were	stage	III.	
According	to	International	Staging	System	[12],	22	were	
stage	I,	16	were	stage	II,	and	10	were	stage	III.	
interphase FisH studies. The	patients	with	at	least	
one	of	the	three	frequent	molecular	cytogenetic	aberra­
tions,	del(13q14),	IGH	rearrangement,	and	Amp1q12	were	
40	(83.3%)	of	the	48	MM	patients.	Of	these	48	patients,	
13	(27.1%)	had	all	three	abnormalities.	21	(43.7%)	showed	
evidence	of	del(13q14).	The	median	number	of	PCs	with	
deletions	was	88%	(range	27~94%).	Rearrangements	in­
volving	14q32	region	were	the	most	common	structural	ab­
normalities,	found	in	29	(60.4%)	patients	and	6	(20.7%)	of	
these	corresponded	to	a	t(11;14)(q13;q32).	Another	part­
ner	4p16	was	identified	in	5	(17.2%)	cases.	Of	9	patients	
with	IGH	rearrangement	and	without	t(11;14)	or	t(4;14)	we	
detected,	none	had	t(14;16)(q32;q23).	24	of	the	48	MM	
patients	(50%)	had	abnormalities	in	chromosome	1	:	1	
with	1	copy	of	1q12,	and	23	with	at	least	3	copies	of	1q12	
(Amp1q12).	Among	21	patients	with	del(13q14),	15	had	
Amp1q12,	and	16	had	 IgH	rearrangement.	Whereas,	
among	27	cases	without	del(13q14),	8	had	Amp1q12,	and	
13	had	IgH	rearrangement.	There	was	a	strong	association	
between	del(13q14)	and	Amp1q12	(χ2	=	8.26, p	<	0.01),	
and	between	del(13q14)	and	IgH	rearrangement	(χ2	=	
3.88,	p	<	0.05).
The	clinical	data	and	FISH	results	of	48	patients	
with	MM	were	presented	in	Table.
Correlation of these three frequent molecular 
cytogenetic aberrations with Durie and salmon 
staging, international staging system and type 
of paraprotein. There	was	no	correlation	between	
del(13q14),	 illegitimate	 IGH	 rearrangement,	 or	
Amp1q12	and	Durie	and	Salmon	staging,	International	
Staging	System,	or	type	of	paraprotein	(p >	0.05).
discussion
MM	cells	are	characterized	by	high	genetic	instabili­
ty,	resulting	in	a	complex	set	of	numerical	and	struc­
tural	chromosomal	abnormalities	[13].	The	detection	of	
genetic	changes	is	important,	not	only	because	of	their	
association	with	clinical	prognosis,	but	also	because	
they	can	be	used	as	measurable	targets	for	response	
to	 treatment.	The	sensitivity	of	detection	of	genetic	
changes	depends	on	 the	methods	used.	Owing	 to	
low	ratio	of	PCs	in	BM	samples	and	the	low	prolifera­
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tive	activity	of	PCs,	it	is	difficult	to	detect	cytogenetic	
changes	by	conventional	R­banding	methods	[14].	We	
enriched	CD138+	myeloma	cells	by	MACS	to	improve	
the	sensitivity	of	the	interphase	FISH	method.	
Recent	studies	based	on	molecular	cytogenetic	
methods	have	shown	that	virtually	all	MM	patients	have	
chromosomal	abnormalities	 in	their	plasma	cells	[15].	
Common	genetic	changes	include	13q	deletion/mono­
somy	13,	 IGH	rearrangement,	chromosome	1	abnor­
mality,	hyperdiploidy,	hypodiploidy,	17p13	deletion,	11q	
deletion,	t(11;14),	t(4;14),	and	trisomy	12	[16–18].	In	this	
study,	we	have	studied	three	prevalent	genetic	changes:	
13q	deletion/monosomy	13,	 IGH	rearrangement	and	
Amp1q12	in	48	patients	with	MM	by	I­FISH	and	detected	
these	aberrations	in	83.3%	of	MM	patients.	
Deletion	of	13q/monosomy	13	 is	common	 in	MM.	
Deletions	of	13q14	have	been	detected	 in	30–50%	of	
MM	patient	samples	by	interphase	FISH	studies,	which	
have	been	seen	as	a	powerful	adverse	prognostic	factor	
in	MM	patients	treated	with	high­dose	chemotherapy	and	
stem	cell	support	[19,	20].	In	our	study,	FISH	analysis	of	
the	13q14	region	was	performed	on	immuno­magneti­
cally	selected	plasma	cells.	We	detected	del(13q14)	in	
21	(43.7%)	of	the	48	MM	patients	with	D13S319	probe.	
The	prevalence	of	the	del(13q14)	is	similar	to	that	most	
other	 investigators	 reported	using	 interphase	FISH.	
However,	it	is	lower	than	that	reported	by	Fiserova13	[13]	
using	interphase	FISH	on	purified	PCs.	PCs	that	scored	
positive	with	 this	deletion	 ranging	 from	27~94%	are	
similar	to	that	reported	by	Chang	(ranging	from	11~85%)	
[21].	We	analyzed	concurrently	the	correlation	between	
del(13q14)	and	Durie	and	Salmon	staging,	International	
Staging	System,or	type	of	paraprotein.	However,	there	
was	no	association	between	them.
Chromosomal	abnormalities	of	14q32	are	the	most	
frequent	chromosomal	abnormalities,	which	have	been	
observed	 in	about	75%	of	patients	with	a	plasma	cell	
malignancy	and	have	been	associated	in	the	oncogenesis	
of	MM	[18].	Five	recurrent	chromosomal	partners	(on­
cogenes)	are	involved	in	IgH	translocations	in	MM:	4p16	
(MMSET	and	usually	FGFR3),	6p21	(cyclin	D3),	11q13	(cy­
clin	D1),	16q23	(c­MAF),	and	20q11	(MAFB).	Together,	the	
combined	prevalence	of	these	five	IgH	translocation	part­
ners	is	about	40%	in	MM,	with	approximately	15%	4p16,	
3%	6p21,	15%	11q13,	5%	16q23,	and	2%	20q11	[22,	23].	
t(4;14)	and	t(14;16)	are	poor	prognosis	factors	[24].	In	our	
series,	IGH	rearrangements	were	found	in	29	of	48	(60.4%)	
MM	patients	with	different	partner	chromosomes:	11q13	
(CCND1)	(6/29,	20.7%),	4	p16(FGFR3)(5/29,17.2%)	and	
other	partners(18/29,62.1%).	In	our	study,	we	found	that	
there	was	no	correlation	between	IGH	rearrangement	and	
Durie	and	Salmon	staging,	International	Staging	System,	
or	type	of	paraprotein.
14q32	translocations	and	del(13q14)	are	not	randomly	
distributed	[25].	Avet­Loiseau	et	al.	[26]	defined	4	major	
genetic	categories	of	patients	according	 to	 the	cor­
relations	between	them:	(1)	patients	lacking	any	14q32	
abnormality	(25%)	and	generally	also	lacking	del(13q14);	
(2)	patients	presenting	either	t(4;14)	or	t(14;16),	almost	
always	associated	with	a	del(13q14)	(15%	of	patients);	
(3)	patients	with	other	14q32	abnormalities	and	present­
ing	del(13q14)	(25%);	and	(4)	patients	with	other	14q32	
abnormalities	but	not	presenting	del(13q14)	(35%).	The	
strong	correlation	might	be	the	basis	for	a	novel	genetic	
classification	of	MM	because	this	genetic	stratification	is	
highly	associated	with	immunological	status	and	clinical	
presentation	and	with	some	major	prognostic	 factors	
and	supports	different	models	 for	MM	oncogenesis.	
In	our	study,	of	48	patients	with	MM,	the	number	of	the	
4	major	genetic	categories	was	19	(39.6%),	5	(10.4%),	
13	 (27.1%),	 and	11	 (22.9%),	 respectively.	 Among	
19	without	illegitimate	IGH	rearrangements,	only	5	har­
bored	del(13q14).	However,	among	29	with	illegitimate	
IGH	rearrangements,	16	had	del(13q14).	Therefore,	
our	study	demonstrates	 that	 the	2	most	 frequent	cy­
togenetic	abnormalities,	14q32	translocations	and	13q	
deletions,	are	strongly	interconnected.	We	then	analyzed	
Table. The clinical data and FISH results of 48 patients with MM
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1 F 50 I I IgAκ no R yes no 2
2 M 56 I I κ no R yes no 2
3 M 67 II I IgAκ 89% yes R yes no 3
4 M 69 III III IgAλ no R yes no 2
5 M 72 III I IgGκ no R yes no 2
6 F 67 III II IgAλ no R yes no 2
7 M 65 II I IgGκ 64% yes R no yes 3
8 M 66 II I IgGκ 89% yes R no yes 3
9 F 56 I II IgGκ no R no yes 2
10 M 59 II II IgGλ no R no yes 2
11 M 65 III III IgGκ 92% yes R no yes 3
12 F 48 I I IgAλ no G no no 2
13 M 55 I I IgGκ no G no no 2
14 M 65 II I IgGκ no G no no 2
15 F 59 II I IgGκ 74% yes G no no 3
16 M 45 III I IgGλ no G no no 2
17 M 75 III I IgAκ no G no no 3
18 F 65 III I IgGκ no G no no 3
19 M 68 I II IgGκ no G no no 3
20 M 71 II II IgAκ no G no no 2
21 F 65 II II IgGκ 93% yes G no no 2
22 M 63 III II IgGκ no G no no 1
23 F 64 III II IgGκ no G no no 2
24 M 66 III II IgGκ no G no no 2
25 M 70 III II IgGλ no G no no 3–4
26 M 75 III II IgGλ 27% yes G no no 2
27 M 72 I III IgGλ 56% yes G no no 3
28 M 63 III III IgGκ no G no no 2
29 M 50 III III IgAκ no G no no 3
30 F 61 III III IgGκ 88% yes G no no 2
31 F 62 I I IgGλ 78% yes R no no 3
32 M 58 I I IgAλ 82% yes R no no no 3–4
33 M 51 II I IgAκ no R no no no 3
34 F 58 II I IgGκ 70% yes R no no 2
35 F 76 II I IgAλ 93% yes R no no no 3
36 F 66 III I IgAκ no R no no 3
37 F 57 III I κ 28% yes R no no 2
38 M 52 III I IgGλ 88% yes R no no 3
39 M 68 III I IgGλ 94% yes R no no no 3
40 M 70 II II IgAκ no R no no 2
41 M 74 II II IgGκ no R no no 2
42 F 71 II II IgGκ 64% yes R no no no 3
43 M 77 III II IgGκ 65% yes R no no 4
44 M 73 III II IgGλ 88% yes R no no no 3
45 M 69 II III IgGλ 90% yes R no no 3
46 M 67 II III IgGλ 94% yes R no no no 2
47 M 58 III III IgGκ no R no no no 2
48 M 68 III III IgAκ no R no no no 4
Notes: *D — S: Durie and Salmon staging; ◊percentage of interphase 
nuclei with one signal and interpretation of findings where “no” indicates 
absence of deletion, “yes” indicates a deletion is present; #R: 14q32 rear-
rangement; G: “germ”( without 14q32 rearrangement); **the number of 
signals of chromosome 1q12.
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the	incidence	of	del(13q14)	in	each	14q32	category	of	
MM.	60%	(3/5)	with	t(4;14)	displayed	del(13q14).This	
percentage	was	dramatically	higher	than	that	observed	
in	t(11;14)	MM	patients,	of	which	only	16.7%	(1/6)	har­
bored	del(13q14)	concurrently.	However,	there	was	no	
significant	difference	between	del(13q14)	incidence	in	
t(4;14)	MM	patients	and	the	incidence	observed	in	the	
overall	population	(60%	versus	41.9%,	p >	0.05).	
Chromosome	1	 instability	 is	also	common	struc­
tural	abnormality,	and	plays	an	 important	 role	 in	 the	
pathogenesis	of	MM.	Chromosome	1	aberrations	are	
frequently	described,	the	short	arm	being	preferentially	
involved	in	deletions	and	the	long	arm	in	gains.	It	was	
reported	that	abnormalities	of	chromosome	1p	and	1q	
were	found	in	36%	and	40%	of	patients	with	an	abnormal	
karyotype	[27].	J.D. Shaughnessy	et	al	[28]	performed	
microarray	analysis	on	 tumor	cells	 from	532	newly	
diagnosed	patients	with	MM.	They	 found	70	genes,	
30%	mapping	to	chromosome	1,	were	 linked	to	early	
disease­related	death.	Importantly,	most	up­regulated	
genes	mapped	to	chromosome	1q,	and	down­regulated	
genes	mapped	to	chromosome	1p,	and	concluded	that	
altered	transcriptional	regulation	of	genes	mapping	to	
chromosome	1	may	contribute	to	disease	progression.	
In	our	study,	we	choose	CEP	1	SpectrumOrange	probe	
to	detect	the	chromosome	1q	aberration	in	48	patients	
with	MM.	47.9%	of	MM	had	amplification	of	chromo­
some	1q.	Amp1q12	was	not	significantly	associated	
with	clinical	staging	and	the	types	of	paraprotein.	 It	 is	
reported	that	gain	of	1q	is	also	associated	with	t(4;14)	and	
chromosome	13	deletion	but	not	t(11;14).	We	found	that	
Amp1q12	was	significantly	associated	with	del(13q14),	
but	not	with	t(11;14)	or	t(4;14).	
In	summary,	our	study	 illustrates	 that	13q	dele­
tion/monosomy	13,	IGH	rearrangement	and	chromo­
some	1	abnormality	are	frequent	in	MM.	They	are	not	
randomly	distributed,	but	 strongly	 interconnected.	
The	correlation	of	 them	with	 the	clinical	prognosis	
should	be	studied	further.	Interphase	FISH	technique	
combined	with	MACS	using	CD138­specific	antibody	
is	a	highly	sensitive	technique	at	detecting	molecular	
cytogenetic	aberrations	and	should	be	used	 in	 the	
routine	evaluation	of	MM.	
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МОЛЕКУЛЯРНЫЕ ЦИТОГЕНЕТИЧЕСКИЕ АБЕРРАЦИИ 
У БОЛЬНЫХ МНОЖЕСТВЕННОЙ МИЕЛОМОЙ, ИЗУЧЕННЫЕ 
МЕТОДОМ ИНТЕРФАЗНОЙ ФЛУОРЕСЦЕНТНОЙ 
ГИБРИДИЗАЦИИ in situ  
Обоснование: множественная миелома (MM) — неизлечимое гематологическое заболевание, характеризирующееся 
накоплением злокачественных плазматических клеток в костном мозге (КM). Клиническая гетерогенность MM определяется 
цитогенетическими аберрациями, присутствующими в клоне плазматических клеток (ПК). Цитогенетические исследования 
MM осложнены гипопролиферативными особенностями ПК. В связи с этим флуоресцентная гибридизация in situ (FISH) 
в комбинации с сортировкой клеток, активированных магнитными полями (MACS) представляется достойной альтернативой 
методам оценки точечных и структурных изменений хромосом при MM. Методы: интерфазные исследования методом 
FISH с использованием трех различных специфических зондов для участков, содержащих 13q14.3 (D13S319), 14q32 
(IGHC/IGHV) и 1q12(CEP1), проводили у 48 больных с MM. Интерфазные исследования методом FISH с использованием 
зондов LSI IGH/CCND1, LSI IGH/FGFR3 и LSI IGH/MAF применяли для детекции t(11;14)(q13;q32), t(4;14)(p16;q32), и 
t(14;16)(q32;q23) у пациентов с перестройкой 14q32. Результаты: молекулярные цитогенетические аберрации выявляли у 
40 (83,3%) из 48 больных с MM. У 13 пациентов (27,1%) одновременно определены 13q делеция/моносомия 13 [del(13q14)], 
аномальная перестройка IGH и аномалия хромосомы 1. Del(13q14) детектировали в 21 случае (43,7%), а аномальные 
перестройки IGH — в 29 (60,4%), в том числе у 6 пациентов с t(11;14) и 5 с t(4;14). Ни у одного из 9 больных с аномальными 
перестройками IGH и без t(11;14) или t(4;14) не выявляли транслокацию t(14;16) (q32;q23). У 24 из 48 пациентов с MM 
(50%) определяли аномалии хромосомы 1. В группе из 21 больных с del(13q14) в 15 случаях имелись перестройки IgH 
Amp1q12;16. В то же время из 27 случаев без del(13q14) у 8 содержались Amp1q12; в 13 случаях отмечали перестройки 
IgH. Выявлена взаимосвязь между del(13q14) и Amp1q12(χ2 = 8,26, p < 0,01) и между del(13q14) и перестройками IgH 
(χ2 = 3,88, p < 0,05). Выводы: 13q делецию/моносомию 13, перестройку IGH и аномалию хромосомы 1 часто отмечают 
при MM, причем их распределение не случайно и тесно взаимосвязано. Интерфазный анализ FISH в комбинации с 
MACS с использованием CD138-специфичных антител является высокочувствительным методом детекции молекулярных 
цитогенетических аберраций при MM.
Ключевые слова: флуоресцентная гибридизация in situ, множественная миелома, цитогенетическая аномалия.
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